Proton pump inhibitors are associated with hypersensitivity reactions to drugs in hospitalized patients: A nested case-control in a retrospective cohort study

Clinical and Experimental Allergy

Volumn 43, Issue 3, 2013, Pages 344-352

  Ramirez E ^a   Cabanas R ^b   Laserna, L S ^a   Fiandor, A ^b   Tong, H ^a   Prior, N ^b   Calderon O ^b   Medrano, N ^a   Bobolea, I ^b   Frias J ^a   Quirce, S ^b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

Drug allergy; Drug hypersensitivity reaction; Hospitalized patients; Pharmacoepidemiology; Pharmacovigilance; Proton pump inhibitor

Indexed keywords

ALLOPURINOL; AMINOGLYCOSIDE DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTACID AGENT; ANTIBIOTIC AGENT; AZTREONAM; CEFAZOLIN; CEFTRIAXONE; CIPROFLOXACIN; CLOXACILLIN; DEXKETOPROFEN; DIPYRONE; IODINATED CONTRAST MEDIUM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLIN DERIVATIVE; PHENYTOIN; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; PROCAINE; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; RIFAMPICIN; SULFONAMIDE; TEICOPLANIN; UNINDEXED DRUG; VANCOMYCIN;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADULT; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONSULTATION; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRESS SYNDROME; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ERYTHEMA; ERYTHEMA MULTIFORME; FEMALE; HAZARD RATIO; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; WARD;

EID: 84873952351     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12034     Document Type: Article

References (48)

1. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost of illness model. Arch Intern Med 1995; 155:1949-56.
2. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329:15-9.
3. Classen DC, Pestotnik SL, Evans RS, Loyds JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra cost, and attributable mortality. JAMA 1997; 277:301-6.
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200-5.
5. DeSharo R, Kemp S. Allergic reactions to drugs and biologic agents. JAMA 1997; 278:1895-906.
6. Demoly P, Hillaire-Buys D. Classification and epidemiology of hypersensitivity drug reactions. Immunol Allergy Clin N Am 2004; 24:345-56.
7. Untersmayr E, Jensen-Jarolim E. The role of protein digestibility and antacids on food allergy outcomes. J Allergy Clin Immunol 2008; 121:1301-8; quiz 1309-10.
8. Untersmayr E, Schöll I, Swoboda I et al. Antacid medication inhibits digestion of dietary proteins and causes food allergy: a fish allergy models in BALB/c mice. J Allergy Clin Immunol 2003a; 112:616-23.
9. Untersmayr E, Bakos N, Schöll I et al. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB J 2005a; 19:656-8.
10. Brunner R, Wallmann J, Szalai K et al. Aluminium per se and in the anti-acid drug sucralfate promotes sensitization via the oral route. Allergy 2009; 64:890-7.
11. Pali-Schöll I, Yildirim AO, Ackermann U et al. Anti-acids lead to immunological and morphological changes in the intestine of BALB/c mice similar to human food allergy. Exp Toxicol Patho 2008; 60:337-45.
12. Pisegna JR. Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition. Crit Care Med 2002; 30(Suppl.6):S356-61.
13. Ramirez E, Lei SH, Borobia AM et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol 2010; 5(4):288-97.
14. Levine BB. Immunologic mechanisms of penicillin allergy: a haptenic model system for the study of allergic diseases of man. N Engl J Med 1966; 275:1115-25.
15. Capellá D, Laporte JR La notificación espontánea de reacciones adversas a medicamentos. In: Laporte JR, Tognoni, G eds. Principios de epidemiología del medicamento. Barcelona: Masson-Salvat, 1993:147-70
16. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretoris during long-term acid suppression with proton pump inhibitors. Alimen Pharmacol Ther 2008; 27:1110-21.
17. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitors therapy and risk of hip fracture. JAMA 2006; 296:2947-53.
18. Bajaj JS, Zadvornova Y, Heuman DM et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009; 104:1130-4.
19. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292:2012-13.
20. Laheij RJ, Van Ijzendoorn MC, Janssen MJ, Cansen JB. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003; 18:847-51.
21. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium-difficile associated diarrhoea. Aliment Pharmacol Ther 2006; 24:613-19.
22. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid suppressive agents and the risk of community acquired Clostridium difficile associated disease. JAMA 2005; 294:2989-95.
23. Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for Campylobacter gastroenteritis: case-control study. BMJ 1996; 312:414-15.
24. Scholl I, Ackermann U, Ozdemir C et al. Anti-ulcer treatment during pregnancy induces food allergy in mouse mothers and a Th2-bias in their offspring. FASEB J 2007; 21:1264-70.
25. Batuwitage BT, Kingham JG, Morgan NE. Bartlett RL Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83:66-8.
26. Barozzi N, Tett SE. Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing. Clin Ther 2009; 31:849-61.
27. De Burgos Lunar, Novo del Castillo S, Llorente Díaz E, Salinero Fort MA. Study of prescription indication of proton pump inhibitors. Rev Clin Esp 2006; 206:266-70.
28. Nardino R, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalised patients. Am J Gastroenterol 2000; 95:3118-22.
29. Noguerado Asensio A, Rodríguez Barrientos R, Zelaya Castro P et al. [Use of acid-suppressive medications in hospitalized patients]. An Med Interna 2002; 19: 557-60.
30. Pham CQD, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother 2006; 40:1261-6.
31. Riemer AB, Gruber S, Pali-Schöll I, Kinaciyan T, Untersmayr E, Jensen-Jarolim E. Suppression of gastric acid increases the risk of developing immunoglobulin E-mediated drug hypersensitivity: human diclofenac sensitization and a murine sensitization model. Clin Exp Allergy 2010; 40:486-93.
32. Gómez E, Blanca-Lopez N, Torres MJ et al. Immunoglobulin E-mediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients. Clin Exp Allergy 2009; 39:1217-24.
33. Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Cin Pharmacol 2011; 71:684-700.
34. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58:33-40.
35. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139:683-93.
36. Fiszenson-Albala F, Auzerie V, Mahe E et al. A 6-month prospective survery of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003; 149:1018-22.
37. Demoly P, Viola M, Gomes ER, Romano A. Epidemiology and causes of drug hypersensitivity. In: Pichler WJ, ed. Hypersensitivity drug. Basel: Karger, 2007:2-17.
38. Mockenhaupt M. Epidemiology and causes of severe cutaneous adverse reactions to drugs. In: Pichler WJ, ed. Hypersensitivity Drug. Basel: Karger, 2007:18-31.
39. Allain H, Chevrant-Breton J, Beneton C et al. Undesirable dermatologic results of drugs. Results of a drug monitoring survey (French). Ann Med Interne (Paris) 1983; 134:530-6.
40. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Programme on 15 438 consecutive patients, 1975 to 1982. JAMA 1986; 256:3358-63.
41. Rademaker M, Oakley A, Dufill MB. Cutaneous adverse drug reactions in a hospital setting. N Z Med J 1995; 108:165-6.
42. Hunziker T, Kunzi UP, Braunschweig S, Zehnder D, Hoigne R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52:388-93.
43. Thong BY, Leong KP, Tang CY, Chng HH. Drug allergy in a general hospital: results of a novel prospective inpatient reporting system. Ann Allergy Asthma Immunol 2003; 90:342-47.
44. Man CB, Kwan P, Baum L et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48:1015-8.
45. Locharernkul C, Loplumlert J, Limotai C et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with the HLA-B*1502 allele in a Thai population. Epilepsia 2008; 49:2087-91.
46. Mehta TY, Prajapati LM, Mittal B et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009; 75:579-82.
47. Kaniwa N, Saito Y, Aihara M et al. HLA -B locus in Japaneses patients treated with antiepileptic or antimicrobial agents. Pharmacogenomics 2008; 9:1617-22.
48. Lonjou C, Thomas L, Borot N et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006; 6:265-8.